结直肠癌（CRC）是全球范围内发病率和死亡率较高的恶性肿瘤之一。HER2 基因扩增在 CRC 中的发生率仅为 3%～5%[1]，但与其预后密切相关，并已成为新的治疗靶点。随着新型 HER2 靶向治疗的出现，针对 HER2 ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application ...

2024年12月4日，北京大学肿瘤医院暨北京市肿瘤防治研究所、消化系肿瘤整合防治全国重点实验室、恶性肿瘤转化研究北京市重点实验室季加孚教授、沈琳教授团队在《自然通讯》（Nature Medicine）杂志上发表了题为“First-line ...

Shares of Leap Therapeutics (NASDAQ:LPTX) tumbled 64% in pre-open trading Tuesday as the company announced that its ...

Adding evorpacept to treatment with trastuzumab, ramucirumab, and paclitaxel may improve outcomes in HER2-positive gastric/GEJ cancer.

Tislelizumab-jsgr approved with chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma, showing significant survival benefits. RATIONALE-305 study demonstrated a 20% ...

Disitamab vedotin already has a conditional approval in China for HER2-positive gastric cancer, and has been filed for HER2-positive bladder cancer on the strength of a pair of phase 2 trials.

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on ALX Oncology Holdings (ALXO – Research Report). The ...

US clinical-stage immuno-oncology biotech ALX Oncology Holdings released positive updated data from the ASPEN-06 Phase II ...

The ASPEN-06 data will be featured in an oral presentation (Abstract #332) at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) earlier the same day.